Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Levocetirizine · Xyzal, Xyzal Allergy 24Hr

Small molecule · Antagonist of histamine H1 receptor (HRH1) · developed by Chattem Sanofi

Approved FDA, May 2007
2 Registered trials

What is Levocetirizine?

Levocetirizine is the active enantiomer of cetirizine, a selective histamine H1 receptor antagonist that competes with endogenous histamine at peripheral H1 receptors. It is studied in allergic rhinitis and is used for allergic symptoms and urticaria.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Xyzal, Xyzal Allergy 24Hr, XYZAL
Drug type
Small molecule
Targets
histamine H1 receptor (HRH1)
Mechanism
Antagonist of histamine H1 receptor (HRH1)
Pathways
histamine signaling, allergic inflammatory response, angiogenesis
Therapy area
Immunology, Respiratory
Developer
Chattem Sanofi
In trials of
NKTR, OGN
FDA status
Approved as Xyzal, Xyzal Allergy 24Hr (May 25, 2007), NDA022064 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 22, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00789152 Phase 3 Allergic Rhinitis Completed OGN
NCT05565729 Phase 1 Healthy Completed NKTR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Allergic RhinitisHealthy

Other drugs acting on HRH1

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.